Head and Neck Squamous Cell Carcinoma
About
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Carboplatin, Fluorouracil, Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Pembrolizumab | |
| Sensitivity (+) | PD-L1 >= 50% | Head and Neck Squamous Cell Carcinoma | Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Carboplatin, Fluorouracil, Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Pembrolizumab |